Please assess the completion status of the following clinical trial:

Trial Title: MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All subjects:~* Pathologically confirmed diagnosis of solid tumors~* Metastatic disease~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1~* Adequate bone marrow, hepatic and renal function~* Normal Electrocardiogram (ECG)~* 18 years of age or above~* Able to understand and sign informed consent~Pilot study only:~- CRC, TNBC, ER/PR Breast Cancer, NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal Junction (GEJ) adenocarcinoma, Head and Neck Cancer~Expansion Phase Additional Criteria:~* Locally advanced or metastatic breast cancer~* Received at least one cytotoxic therapy in the locally advanced and metastatic setting~* Received ≤ 5 prior lines of chemotherapy in the metastatic setting~* Candidate for chemotherapy~Expansion Phase Cohort 3 additional inclusion criteria:~* Breast cancer with active brain metastasis~* Neurologically stable~Exclusion Criteria:~* Active Central nervous system (CNS) metastasis (applies to pilot phase and expansion phase cohort 1 and 2 only)~* Clinically significant GI disorders~* Prior irinotecan or bevacizumab therapy within last 6 months and for Expansion Phase patients, have received any prior treatment with Topol inhibitor~* Known hypersensitivity to MM-398 or ferumoxytol~* Inability to undergo MRI~* Active infection~* Pregnant or breast feeding~* Prior chemotherapy administered within 3 weeks, or within a time interval less than at least 5 half-lives of the agent, whichever is longer, prior to the first scheduled day of dosing in this study~* Received radiation therapy in the last 14 days~* Treated with parenteral iron in the previous 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pilot Phase: Ferumoxytol followed by MM-398 (Type: EXPERIMENTAL): Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min on Days 1 and 15 of every 4 week cycle
- Expansion Phase: Ferumoxytol followed by MM-398 (Type: EXPERIMENTAL): Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min dose 1 on Days 1 and 15 of every 4 week cycle Cohort 1: ER and/or PR-positive BC Cohort 2: TNBC Cohort 3: BC with active brain metastasis

Based on this trial design, predict the completion outcome and termination type (if applicable).